Clinical Trials
8 trialsNCT00535951 2020-12-19
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Novartis
Phase 1 Completed
NCT00997399 2020-12-19
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
Novartis
Phase 1 Completed
NCT01007968 2020-12-19
Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function
Novartis
Phase 1 Completed
NCT00878904 2017-03-24
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT00550199 2013-08-19
LBH589 and Gemcitabine in the Treatment of Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT01055795 2012-12-24
BEL
Duke University
Phase 1 Completed
NCT01159418 2011-09-13
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
Southern Europe New Drug Organization
Phase 1 Unknown
NCT00556088 2010-12-30
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed